Partners
Yale University
We have collaborated intensively for many years with researchers in Dr. Edelson’s lab in the Department of Dermatology at Yale School of Medicine. Dr Edelson and colleagues were the pioneers of extracorporeal photopheresis and continue to uncover insights into the central role of platelet-activated dendritic cells and how to broaden their usage into new disease indications. Yale are a valued research partner in Transimmune's work with the Bill & Melinda Gates Foundation and under the ARPA-H grant.
EMORY University
Dr. Santangelo’s lab at Emory University are world leaders in the research of mRNA vaccines and therapeutics, particularly in the field of infectious diseases. Emory are a valued research partner in Transimmune’s work with the Bill & Melinda Gates Foundation and under the ARPA-H grant.
Investors
QureInvest
QureInvest is an entrepreneurial investment fund managed by HS LifeSciences, committed to invest in early-stage companies within the medical innovation sector.
Partnering Contact
Mr Duckworth is a founder of Transimmune and became CEO in 2022. Prior to that he was a healthcare venture capitalist of 22 years, most recently as Managing General Partner of QureInvest Fund. In addition to fund management, he was heavily involved in corporate development for portfolio companies Ethris and Transimmune. Prior to QureInvest, he was a Partner at Nomura Phase4 Ventures and an advisor at HBM Partners. He studied biochemistry at the Oxford University and is an ACA.